GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (STU:PX91) » Definitions » Accounts Payable

Cassava Sciences (STU:PX91) Accounts Payable : €7.31 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cassava Sciences Accounts Payable?

Cassava Sciences's Accounts Payable for the quarter that ended in Dec. 2024 was €7.31 Mil.

Cassava Sciences's quarterly Accounts Payable declined from Jun. 2024 (€48.82 Mil) to Sep. 2024 (€47.07 Mil) and declined from Sep. 2024 (€47.07 Mil) to Dec. 2024 (€7.31 Mil).

Cassava Sciences's annual Accounts Payable increased from Dec. 2022 (€3.79 Mil) to Dec. 2023 (€9.70 Mil) but then declined from Dec. 2023 (€9.70 Mil) to Dec. 2024 (€7.31 Mil).


Cassava Sciences Accounts Payable Historical Data

The historical data trend for Cassava Sciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Accounts Payable Chart

Cassava Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 6.31 3.79 9.70 7.31

Cassava Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.70 8.84 48.82 47.07 7.31

Cassava Sciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Cassava Sciences Accounts Payable Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Cassava Sciences Headlines

No Headlines